Taysha Gene Therapies, Inc. (TSHA) return on equity (ROE)

Return on equity · fiscal 2025
-44.1%

Taysha Gene Therapies, Inc. (TSHA) earned a return on equity of -44.1% in fiscal 2025 (the year ended December 31, 2025). That is 80.7 percentage points higher than the -124.8% of fiscal 2024. Figures as of 17 Nov 2026, 21:14 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Return on equity, fiscal 2025
-44.1%
Change on fiscal 2024
+80.7 pts
Highest on record
-23.9%fiscal 2020
Lowest on record
-17493.6%fiscal 2022
Fiscal years on record
62020–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

Taysha Gene Therapies, Inc. return on equity (ROE), in more detail

Across the 6 fiscal years on record (2020–2025), the highest was -23.9% in fiscal 2020 and the lowest -17493.6% in fiscal 2022. The fiscal 2025 figure is higher than in 80% of the 5 earlier fiscal years on record, whose median is -148.9%.

History · 6 fiscal years

Return on equity by fiscal year

Taysha Gene Therapies, Inc. return on equity (ROE), year by year

Taysha Gene Therapies, Inc. (TSHA) return on equity (ROE) by fiscal year
Fiscal yearReturn on equityChangeYear ended
2025-44.1% 80.7 pts up
2024-124.8% 24.0 pts up
2023-148.9% 17344.7 pts up
2022-17493.6% 17310.6 pts down
2021-183.0% 159.1 pts down
2020-23.9%—

Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

How to read it

It is the profit earned on the owners' capital — above about 15% is strong, though heavy debt or large buybacks can inflate it.

More on TSHA

Taysha Gene Therapies, Inc., figure by figure

Taysha Gene Therapies, Inc. (TSHA) overview: price, valuation and scorecard

Taysha Gene Therapies, Inc. return on equity (ROE): questions and answers

What is Taysha Gene Therapies, Inc.'s return on equity?

Taysha Gene Therapies, Inc. (TSHA) earned a return on equity of -44.1% in fiscal 2025 (the year ended December 31, 2025). That is 80.7 percentage points higher than the -124.8% of fiscal 2024.

Is Taysha Gene Therapies, Inc.'s return on equity high or low compared with its own history?

The fiscal 2025 figure is higher than in 80% of the 5 earlier fiscal years on record, whose median is -148.9%.

What are the highest and lowest return on equity figures on record for Taysha Gene Therapies, Inc.?

Across the 6 fiscal years on record (2020–2025), the highest was -23.9% in fiscal 2020 and the lowest -17493.6% in fiscal 2022.

How is Taysha Gene Therapies, Inc.'s return on equity calculated?

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Taysha Gene Therapies, Inc. (TSHA) return on equity (ROE)”, data as of 17 November 2026. https://funkfolio.com/stock/TSHA/roe

Underlying data: the company's filings with the SEC and Yahoo Finance.